Bradley beefs up reps for launch

Share this article:
Bradley Pharmaceuticals is hiring about 60 reps as it gears up to launch Elestrin, a low-dose estrogen gel for treating the symptoms of menopause.

The reps will pitch Elestrin to OB/GYNs as part of Bradley's Kenwood Therapeutics division, which received FDA approval for the product last December.

The company estimates the size of the US estrogen therapy market, which consists of oral and topical products, at $1.3 billion. The topical market is only worth about $300 million. Bradley in-licensed Elestrin from BioSante Pharmaceuticals late last year and has the exclusive US marketing rights.

Share this article:

Email Newsletters

More in News

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi and partner Regeneron attached a $67.5-million priority review voucher to their experimental cholesterol drug alirocumab, miaking for a tighter race with Amgen.

AstraZenca beefs up respiratory portfolio

AstraZenca beefs up respiratory portfolio

AstraZeneca has made an $875-million move to beef up its respiratory pipeline by making Almirall's lineup its own.

Amgen Q2 sales rise, company to lay off up to 2,900

Amgen Q2 sales rise, company to lay off ...

The majority of the layoffs will be in the US.